Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Nov;346(5):482-5.
doi: 10.1007/BF00169000.

Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle

Affiliations

Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle

U Jahnel et al. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov.

Abstract

The effects of 5-hydroxytryptamine (5-HT) on force of contraction (FC), action potential (AP) and calcium current (ICa) were studied in human right atrial and left ventricular heart muscle. 5-HT exerted a concentration-dependent increase in FC in multicellular atrial preparations; the EC50 was approximately 3 x 10(-7) mol/l. Maximal increases in FC (252 +/- 58% of control values; mean +/- SEM, n = 6) were obtained at 5-HT 10(-5) mol/l. At this concentration, ICa was increased four- to sevenfold in enzymatically isolated atrial myocytes. In contrast, ventricular preparations did not respond to 5-HT; FC, AP and ICa remained unaffected. In the same preparations, FC was increased by isoprenaline three- to fourfold. These results confirm the observation that 5-HT induces a positive inotropic effect in the human atrium, possibly mediated by activation of the adenylyl cyclase - cyclic AMP system. Our study demonstrates, however, the complete lack of functional 5-HT receptors, with respect to changes in FC, in the human ventricle. Since the positive inotropic effect of 5-HT in the human heart is obviously restricted to the atrium, our findings question the concept of developing 5-HT receptor agonists for the treatment of heart failure.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mol Pharmacol. 1988 Dec;34(6):880-7 - PubMed
    1. Pflugers Arch. 1981 Aug;391(2):85-100 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):382-6 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1985 Aug;330(2):121-9 - PubMed
    1. Mol Pharmacol. 1992 Feb;41(2):346-51 - PubMed

Publication types

LinkOut - more resources